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Educational aims
●● To give specialist respiratory clinicians practical clinical tools to help improve the quality of life of 
their patients with advanced respiratory disease and chronic breathlessness.
●● To outline the evidence base for these interventions with reference to definitive sources.
●● To highlight the importance of person-centred care in people with respiratory disease at all stages 
of illness.
Key points
●● People living with advanced respiratory disease and severe chronic breathlessness (and those 
closest to them) have a poor quality of life.
●● Chronic breathlessness is a disabling symptom, and acute-on-chronic/episodic breathlessness is 
frightening to experience and observe.
●● Chronic breathlessness imposes profound physical limitations and psychosocial burdens on those 
suffering from it or living with someone experiencing it.
●● Fatigue and cough are two other cardinal symptoms of advanced respiratory disease, with very 
detrimental effects on quality of life.
●● The impact of all these symptoms can be alleviated to a variable extent by a predominantly non-
drug complex intervention.
●● Many of the interventions are delivered primarily by allied health or nursing professionals.
●● Doctors, nurses and other health professionals also need to play an active part in promoting quality 
of life as part of excellent medical care.
●● A person-centred, psychologically informed approach is needed by all clinicians treating patients 
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Improving quality of life in people with chronic breathlessness, with a combination of (mostly) 
non-drug and drug interventions, improves clinical outcomes and reduces patient/carer suffering 
and futile use of medical services http://bit.ly/30s9ckh
Advanced respiratory disease imposes a greater symptom burden than many cancers but not does 
have comparable recognition of the need for supportive and palliative care or the infrastructure 
for its systematic delivery. Consequently, many people with advanced respiratory disease (and 
those closest to them) have a poor quality of life, disabled by chronic breathlessness, fatigue and 
other symptoms. They are socially isolated by the consequences of long-term illness and are 
often financially impoverished. The past decade has seen an increasing realisation that care for 
this group must improve and that symptom management must be prioritised. Clinical guidelines 
recommend person-centred care, including access to supportive and palliative care as needed, 
as part of standard medical practice. Advanced lung disease clinics and specialist breathlessness 
services (pioneered within palliative care) are developing within respiratory medicine services but 
are provided inconsistently.
This review covers the comprehensive assessment of the patient with advanced respiratory 
disease, the importance of supporting carers and the current best practice in the management of 
breathlessness, fatigue and cough. It also suggests ways to incorporate person-centred care into 
the general respiratory clinic, assisted by better liaison with specialist palliative and primary care. 
Emerging evidence shows that excellent symptom management leads to better clinical outcomes 
and reduces inappropriate use of emergency medical services.
Cite as: Booth S, Johnson 
MJ. Improving the quality of 
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Improving the quality of 
life of people with advanced 
respiratory disease and 
severe breathlessness
Introduction
People living with advanced respiratory diseases 
do not receive the supportive and palliative care 
that they need to have the best possible quality 
of life [1–4]. Globally, many millions of people live 
with advanced respiratory diseases [5], including 
chronic obstructive pulmonary disease (COPD) 
and interstitial lung disease (ILD). Most affect 
middle-aged to older people but some (e.g. 
lymphangioleiomyomatosis (LAM) and cystic 
fibrosis) affect teenagers and young adults. The 
diseases may be rapidly progressive or have 
a more chronic course and younger patients 
may be awaiting hazardous treatments such 
as lung transplantation. However, in all, as the 
disease progresses, the patient becomes highly 
symptomatic and improvement is unlikely despite 
maximum treatment of the underlying condition.
While there is no comparable infrastructure to 
cancer medicine for providing supportive and gen-
eralist palliative care in respiratory medicine, it is 
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recognised that the deficit in symptom control and 
psychosocial support leads to a poorer quality of 
life for patients not only with advanced respiratory 
 disease [1, 4] but also across the general population 
[6, 7], and this is likely to have a negative effect on 
medical outcomes. It also leads to appreciable, futile 
use of expensive out-of-hours medical services, pri-
marily associated with a failure to manage the severe 
breathlessness experienced by these patients [7]. 
It is therefore the responsibility of every respiratory 
clinician to provide the best “person-centred” care 
they can, by ensuring they use all the resources and 
expertise available to them. Typically, the “acute” of 
the acute-on-chronic breathlessness only is man-
aged and the “chronic” is left untreated [4, 7–9]. The 
physical and mental demands of caring for someone 
with a chronic illness have long been established 
in the research literature, particularly if that person 
has breathlessness [10, 11]. These burdens lead to 
long-term health impacts in carers and increasing 
societal financial costs, as well as individual suffer-
ing; yet, there is very little formal recognition of the 
need to support carers.
Supportive care overlaps with palliative care, 
although patients receiving palliative care are 
generally expected to have advanced and progressive 
disease, often categorised as “death considered to 
be unsurprising within the next year” [12]. However, 
as most non-cancer conditions, and indeed now 
many cancer diagnoses, have a chronic, fluctuating 
trajectory, punctuated by relapses and remissions, 
with cumulating morbidity from the effects of 
treatment and disease, a needs-based approach rather 
than one based on prognosis is more appropriate 
in people with advanced respiratory disease. The 
principles of both supportive and palliative care are 
the same: provision of person-centred, integrated 
care for patient and family. Therefore, the term 
“person-centred care”, becoming recognised as a 
hallmark of excellent care, is used throughout this 
review and removes any discussion about when 
someone is “ready” for palliative care. Person-
centred care also encompasses the choice of 
disease-directed treatments for the individual, 
and thus provides a basis on which to ensure 
patients receive individualised disease treatment 
and also have their symptoms and other concerns 
identified and addressed. If person-centred care is 
in place, appropriate supportive and palliative care 
should follow. The details of these definitions are 
summarised in table 1.
This review is written for the specialist 
multiprofessional respiratory team, to help each 
member contribute to the delivery of excellent 
person-centred care for patients and families living 
with advanced respiratory disease. It outlines the 
current evidence for a person-centred approach 
and its beneficial impact on clinical outcomes, 
highlighting that a focus on quality of life needs 
to become an integral part of clinical practice. 




Person-centred care is a way of thinking and doing 
things that sees the people using health and social 
services as equal partners in planning, developing 
and monitoring care to make sure it meets their 
needs.
Least ambiguous term, unrelated to prognosis.
Most important in chronic conditions where there is 
no disease-altering therapy and patient engagement 




An approach “to prevent or treat as early as possible 
the symptoms of a disease, side-effects caused by 
treatment of a disease, and psychological, social 
and spiritual problems related to a disease or its 
treatment”.
Has become central to cancer medicine (and 
an expectation), where supportive services are 
advanced, although symptom burden in a number 
of cancers may be much less and disease may be 
completely curable.
Accepted that “lifestyle” interventions will lead to 
greater long-term health.
Many people with cancer live with “treatable but 
not curable” disease, like those with advanced 




Palliative care is an approach that improves the 
quality of life of patients and their families facing 
the problems associated with life-threatening 
illness, through the prevention and relief of suffering 
by means of early identification and impeccable 
assessment and treatment of pain and other 
problems, physical, psychosocial and spiritual. 
Will enhance quality of life and may also positively 
influence the course of illness.
Favoured by the European Respiratory Society for 
people with advanced disease and where death 
would not be unexpected.
The World Health Organization also states: “Is 
applicable early in the course of illness, in 
conjunction with other therapies that are intended 
to prolong life, […] and includes those investigations 
needed to better understand and manage distressing 
clinical complications”.
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It briefly discusses how to give specific interventions 
as well the rationale for them, recognising the time 
pressures of routine clinical practice. Ultimately, 
good person-centred care is likely to reduce costs 
of money and time and improve clinical outcomes 
[16, 17]. This review does not consider care of the 
dying, nor improving quality of life in patients with 
cancer, both of which are well reviewed in standard 
texts [18, 19] and recent papers [20].
The cardinal symptoms of advanced respiratory 
disease are troublesome breathlessness, fatigue and 
cough [4, 21], sometimes called “the respiratory 
triad” [21]. All these symptoms can be invisible at 
rest, needing active elicitation to detect them. The 
science of symptom management has improved 
in recent years and failure to address these in 
specialist respiratory services should now be 
seen as inexcusable [19, 22]. Many patients have 
Box 1 The five ways to well-being
Be active
Go for a walk or run. Step outside. Cycle. Play a game. Garden. Dance. Exercising makes you feel good. Most importantly, discover 
a physical activity you enjoy and that suits your level of mobility and fitness.
●● Exercise is good for health, both physical and psychological.
●● Exercise (weight-bearing) gives some protection from osteopenia/osteoporosis (e.g. common with long-term steroids or 
inactivity).
●● Exercise protects against heart disease.
●● Exercise reduces the chance of cancer and/or recurrence of cancer.
●● Allied health professionals/nurses can expertly help people find exercise suitable for their health status.
●● Exercise is good for reducing sensation of breathlessness.
Connect
Connect with the people around you. With family, friends, colleagues and neighbours. At home, work, school or in your local 
community. Think of these as the cornerstones of your life and invest time in developing them. Building these connections 
will support and enrich you every day.
●● Social isolation is bad for health.
●● Encourage patients to strengthen their social network, particularly if they use oxygen or feel stigmatised for any reason.
●● Informed social networks (e.g. Breathe Easy, Men in Sheds) can offer support when other networks (e.g. some friends) 
disappoint.
●● “Connect” is often associated with “Be active” and “Keep learning”.
Take notice
Be curious. Catch sight of the beautiful. Remark on the unusual. Notice the changing seasons. Savour the moment, whether you 
are walking to work, eating lunch or talking to friends. Be aware of the world around you and what you are feeling. Reflecting 
on your experiences will help you appreciate what matters to you.
●● Rumination predisposes to depression, which is associated with worse health outcomes (and linked to social isolation).
●● Mindfulness training (mindfulness-based stress reduction) is an evidence-based way to encourage living in the present 
and reducing rumination.
●● Other models of building psychological health include health coaching and “buddying systems”
Give
Do something nice for a friend or a stranger. Thank someone. Smile. Volunteer your time. Join a community group. Look out, 
as well as in. Seeing yourself, and your happiness, linked to the wider community, can be incredibly rewarding and creates 
connections with the people around you.
●● Altruism is good for health and for building personal resilience, although excess can be harmful.
●● Allied health professionals/nurses can help individuals participate in health-building altruistic activities and, where 
necessary, help people give themselves permission to not be altruistic.
Keep learning
Try something new. Rediscover an old interest. Sign up for that course. Take on a different responsibility at work. Fix a bike. 
Learn to play an instrument or how to cook your favourite food. Set a challenge you will enjoy achieving. Learning new things 
will make you more confident as well as being fun.
●● People with chronic illness experience many social losses; learning new skills may be a necessity for employment, for 
helping social confidence and morale.
●● It can be a way of managing stress, anxiety and any symptoms.
Compiled by the New Economics Foundation, within the UK Government’s Foresight project. Reproduced and modified from [24] with permission.
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multimorbidities from the complications of their 
respiratory or unrelated illness(es), or their long-
term treatment (e.g. steroids). A comprehensive 
assessment will encompass appraisal of all 
symptoms, even if only to ensure all are being 
actively managed by someone, e.g. in primary care.
Other factors that strongly affect quality of 
life and clinical outcomes, but which are mainly 
outside the clinical sphere of influence (e.g. social 
impacts on clinical outcomes), are shown in table 2 
together with suggestions of how clinicians may at 
least direct patients and families to sources of help. 
Box 1 outlines suggestions for how well-being and 
general health may be improved.
Some of the interventions recommended in this 
review are central to the practice of allied health 
professionals (e.g. breathing exercises), others 
to nurses (e.g. a supportive approach to patient 
and family with general health counselling), and 
others to physicians and other prescribers (e.g. 
drug therapy). All are discussed so that, even if 
not routinely delivered by an individual clinician, 
each clinician is equipped to endorse them and 
refer patients knowledgeably, which may help 
improve the intervention’s impact and the patient’s 
confidence in the multiprofessional team.
Breathlessness
The most commonly used definition of 
breathlessness is from an American Thoracic 
Society working group, which described it as “a 
subjective experience of breathing discomfort 
that consists of qualitatively distinct sensations 
that vary in intensity” [25]. Recently Johnson et al. 
[26] have defined chronic breathlessness syndrome 
as “breathlessness that persists despite optimal 
treatment of the underlying pathophysiology and 
that results in disability”, to make it easier for 
clinicians to identify and recognise it as a treatable 
condition, for patients to volunteer it in clinical 
encounters, and to drive service development. 
Treatable does not mean reversible: most 
breathlessness management aims to reduce the 
impact of the breathlessness on an individual’s 
life or increase the threshold of activity at which 
breathlessness becomes limiting. It is important 
to clarify this when discussing treatment.
Chronic breathlessness in 
advanced respiratory disease
Although chronic breathlessness in advanced 
respiratory disease results from a number of 
pathophysiological processes, such as cachexia, 
deconditioning and airway narrowing [19], the 
sensation of breathlessness originates from 
complex neurophysiological interplays between 
the automaticity of the breathing centre in the 
brain stem, the generation of fear/anxiety in the 
amygdala and limbic system and the influence 
of the higher, cortical thinking and feeling areas 
(simplified in figure 1). The cortical areas that 
represent breathlessness are adjacent to other 
“alarm” centres for thirst and pain, for example. The 
areas involved in the generation of breathlessness 
do not “fire off” as independent units but interact 
as a complex network.
A recent paper by Ongaro and Kaptchuk 
[28] discussed ways in which symptoms may be 
generated within complex brain networks. They 
postulate that perception is “cognitively modulated 
(mostly unconsciously) and might best be viewed 
as a process of prediction based on sensory inputs, 
prior experience and contextual clues”. For example, 
according to the Bayesian brain hypothesis (figure 2) 
[29], someone who has always been very breathless 
on climbing stairs may well become anxious even 
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Figure 1 Schematic diagram to outline the genesis of breathlessness. Reproduced and modified 




Figure 2 Schematic of the Bayesian brain hypothesis. Both prior expectations and incoming 
sensory information contribute to the resulting perception, where each is a distribution of possi-
ble values. Reproduced from [29] with permission.
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their climb. They may avoid stairs and become 
less fit. Practical help from a trusted clinician 
may help them find new ways of approaching this 
previously insuperable obstacle (e.g. by replacing 
old cognitions and perceptions and learning more 
efficient breathing techniques).
It is also essential to remember that the 
central nervous system (CNS) and the endocrine 
and immune systems are intimately related and 
mutually influence each other; this mind–body 
integration is encapsulated by the concept of 
psychoneuroimmunology [30]. Usefully, this 
means that an improvement in one system (e.g. 
reduced impact of breathlessness) is likely to lead 
to an impact in another (e.g. reduced stress), but 
the opposite also holds, contributing to the impact 
of breathlessness on an individual’s health.
The genesis of breathlessness continues to be 
elucidated. The central concept is that the sensation 
comes from, and is a construct of, the CNS. When all 
possible treatment of pathophysiological processes 
has been accomplished, further management will 
involve the patient using a psychologically informed 
approach to their condition with the clinician 
helping them to improve peripheral generators of 
breathlessness, such as muscle deconditioning. 
Peripheral generators of breathlessness sometimes 
result from a secondary, ultimately unhelpful, 
behavioural consequence of breathlessness itself, 
such as inactivity or social isolation [25, 30]. These 
relationships are shown in figure 3 and are known as 
the spiral of disability. This concept was recognised 
many years ago by Comroe [31], who stated that 
breathlessness, “like pain, … involves both the 
perception of the sensation by the patient and his 
reaction to the sensation”. This has more recently 
been understood as the “sensory” and “affective” 
aspects of breathlessness [19, 32]. Understanding 
this offers pathways to symptom management 
through helping the individual to alter their learned 
response to breathlessness.
Breathlessness severity is a better indicator 
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Figure 3 The spiral of disability.
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Figure 4 The BTF model of breathlessness used by the Cambridge Breathlessness Intervention Service (CBIS). ©2017 
CBIS. Reproduced with permission from the CBIS and Cambridge University Hospitals NHS Foundation Trust. Modified 
from [37].
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than lung function, as there is no consistent 
relationship between lung function and degree 
of breathlessness [33]. This is probably because 
breathlessness is related to many general health 
and social factors, such as degree of motivation, 
general fitness, burden of anxiety and depression, 
social isolation, etc., and again, understanding this 
opens ways to improve the symptom.
The idea of treating breathlessness “via the 
brain” [29, 34, 35], supporting and educating 
the breathless person in self-management [2], is 
gaining ground, and so is the understanding that 
“stimulation of the failing organ” alone [36] will 
be futile.
A conceptual model for the clinical 
management of breathlessness
Spathis et al. [37] have developed a “Breathing, 
Thinking, Functioning” (BTF) model to help 
clinicians, patients and carers understand the 
generation of breathlessness and the ways in which 
they can participate in and/or lead its management 
(figure 4). The model postulates that there are 
three broad “classes” of factors that contribute to 
the generation of breathlessness and can thus be 
understood and acted upon to increase or decrease 
the symptom. 1) The “Breathing” cycle: e.g. an 
inefficient, ineffective breathing pattern such as 
rapid shallow breaths, leading to a vicious cycle of 
increased breathlessness, often associated with 
perpetuating anxiety. 2) The “Thinking” cycle: 
problems with cognitions that the patient (and 
carer) hold about breathlessness, e.g. “one day 
I’m going to die gasping for breath”, which drives a 
vicious cycle of perpetuation through anxiety. The 
mistaken cognitions give rise to emotions that 
exacerbate breathlessness. 3) The “Functioning” 
cycle: the patient’s dominant problem is in the 
area of fitness and reduced physical and mental 
activity, e.g. he/she has become deconditioned 
from inactivity, perhaps initiated by avoiding 
exercise to avoid breathlessness and/or anxiety, 
and a vicious cycle of deconditioning and increasing 
breathlessness ensues (figure 3).
It is clear that these cycles are interconnected 
and not mutually exclusive, but one vicious 
cycle often predominates in an individual and 
drives others. Highlighting one cycle as a focus 
for treatment gives an early indication of which 
management strategies to prioritise, as well as 
making it easier to explain the rationale behind the 
treatment strategy to patient and family, facilitating 
engagement in self-management.
Patients who frequently attend the accident 
and emergency department, call their general 
practitioner (GP) out of hours, or come into hospital 
with nothing specifically disease-related to treat, 
should have a comprehensive assessment (see 
the ideal in figure 5). In these situations, lack of 
symptom control and/or psychosocial distress in 
the patient or carer are likely to be contributing to 
frequent futile use of clinical services, and change 
is unlikely unless these are addressed. Unless 
the “chronic” aspects of “acute-on-chronic” 
breathlessness are managed [7], the factors that 
led to an emergency presentation remain and 
  Full SOB history, including
    numerical record of severity using  
    tool like D12.
  BTF analysis with appropriate
    interventions explained.
  Physiotherapist/OT/specialist 
    nurse referral.
  Specialist palliative care support:
    either advice or referral.
  Pharmacological therapy initiated 
    where indicated.
  Acknowledge the problem of breathlessness, 
    listen to major concerns, say it’s possible to 
    help but needs time.
  Explain/give hand-held fan/refer to   
    respiratory physiotherapist for further 
    assessment, breathing exercises, mobility 
    aids, community support.
  If access to specialist nurse, refer for 
    detailed assessment.
  If severe SOB, discuss bringing back earlier 
    to address, and speak to primary care. Give 
    written information or refer to online 
    information (BLF, BTS, CBIS).
  Highlight problems of patient/carer in 
    letter: recommend referral to specialist 
    palliative care if complex or very breathless.
Establish that the patient is troubled by breathlessness
  Ignore symptoms or ask about 
    symptoms and then ignore.
  Fail to refer to colleagues
    (physiotherapist, OT or 
    specialist nurse) for help. Do 
    not communicate with primary 
    care.
  Routine follow-up with repeated 
    lack of person-centred care.
Ideal Making a good start Unhelpful
Figure 5 First-step algorithm for a busy general respiratory clinic without specialist breathlessness/supportive care service. SOB: shortness of breath; 
D12: Dyspnoea-12; OT: occupational therapist; BLF: British Lung Foundation; BTS: British Thoracic Society.
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may initiate a further emergency visit or frequent 
attendance in primary care.
The consultation: assessing 
patients with severe 
respiratory disease
Assessment is the step that defines the quality of 
person-centred care given to the individual with 
advanced respiratory disease. If it is inadequate 
then major symptoms (and other concerns) 
will not be elicited and potentially, if carried out 
insensitively, the clinician–patient relationship 
will be impaired, with a negative effect on clinical 
outcomes. It is essential to find out the patients’ 
main concerns. There is extensive work to show 
that there are marked differences between patients’ 
and physicians’ concerns in a consultation [38]. In 
an incurable, highly symptomatic illness where 
improving quality of life is the main goal, the 
patient’s goals of care are paramount.
Eliciting symptoms
Even people with severe breathlessness may 
not look breathless when sitting quietly in the 
consultation room; this is part of the phenomenon 
which Gysels and Higginson [9] called “the 
invisibility of breathlessness”. They highlighted that 
this may contribute to the reasons that patients 
with COPD do not get appropriate care. Only those 
with the most severe disease and worst prognosis 
are breathless at rest. They are unlikely to be 
well enough to visit the outpatient department. 
Patients may not volunteer difficult symptoms if 
they are completely exhausted from the strain of 
reaching the hospital outpatient clinic and may 
not feel emotionally or even cognitively powerful 
enough to make their needs felt or explain their 
symptoms. They may think that the clinician is not 
interested in how they feel, as accepted treatments 
for chronic breathlessness, fatigue and cough 
have only recently been established. Patients 
may have discerned from previous consultations 
Box 2 Assessment of chronic breathlessness: areas to be covered
Introduction
Read the notes and greet the patient/family by name. It is very distressing for patients if the clinician appears to have no 
knowledge of the patient or even makes basic mistakes, e.g. in diagnosis. This does not preclude you from making your own 
assessment of key issues.
Questions to establish history of breathlessness
Are you troubled by breathlessness?
What makes you breathless?
What helps your breathlessness?
What have you stopped/reduced doing to prevent you getting breathless?
Are you breathless when you are sitting completely still?
What happens when you feel breathless? (e.g. How does it come on? How do you try to improve it? How long before you feel 
better? What makes it better/worse? Are you taking any medications to help it?)
(Ask carer) What do you notice when patient X becomes breathless?
How do you feel when you become breathless? Some people say being breathless makes them feel very anxious, some people 
even use the word panicky. Does that sound familiar? Have you always been troubled by anxiety?
What do you think is causing your breathlessness? (Ask the carer the same question)
Do you have times when a worsening of breathlessness does not settle as usual, or when it seems to come out of the blue/from 
nowhere? (Start asking about feelings/emotions/thoughts about breathlessness, which may be triggering breathlessness 
without the patient being aware of what is preceding it) [40]
Was there a particular episode after which your breathlessness seemed to get much worse? (It is not uncommon for there to be 
an episode of breathlessness that is particularly frightening or associated with panic, after which breathlessness seems to get 
much worse generally, i.e. a “trigger” episode. Unpicking this, e.g. with the BTF model, may help bring about improvement.)
What do you when this kind of crisis happens? And your wife/husband/carer/partner or other carer? (Gives a basis for education 
and “ritual for crises”) [18, 41]
Have you attended pulmonary rehabilitation? If yes: how you did/felt about it/changes made afterwards. If not: why was this? 
e.g. lack of confidence, not referred, not available, etc. and rectify or consider specialist palliative care, advanced lung clinic, etc.
What is the worst thing for you at the moment? (Ask carer too. Note: this may not be breathlessness, may be cough, fatigue or 
other concern. Ask about cough and fatigue using similar questions. See text and other boxes.)
Summarise and plan
Summarise what you have learned, for the patient to check.
Lead onto management plans, for example:
This is a very difficult symptom and sounds as if it is making life very hard for you. There has been a lot of research in this area 
in recent years and now we do have ways we can help.
It does take a bit of time and work and different skills from different members of the team working together.
I would like you to meet…
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that mentioning symptoms was futile [39]. Some 
patients may have episodic breathlessness [8] 
and, although this is overwhelming at the time, it 
is not made evident in the outpatient clinic unless 
information is explicitly sought.
Therefore, it is essential that the clinician asks 
about symptoms actively [22]. Evidence suggests 
that consultation time is saved when simple open 
questions are asked to enable the patient to make 
clear their needs and the impact of breathlessness 
on their everyday life and that of their family. After 
a general opening, e.g. addressing recent acute 
events, direct enquiry about symptoms is crucial 
(see box 2 for suggestions). This should include 
the activities that precipitate the symptom and the 
activities they have stopped or reduced in order to 
remain comfortable. A simple “Are you breathless?” 
may elicit a “No”. The clinician then misses not only 
the presence of the symptom, but also the severe 
and widespread limitations that follow from chronic 
breathlessness.
It is important to avoid a quick-fire litany of 
questions, without waiting for the patient to give 
answers. If the patient does have troublesome 
chronic breathlessness, but there is no time 
for a comprehensive symptom assessment 
and management, start by acknowledging the 
importance of what the patient is telling you, 
explain that it is possible to help reduce the impact 
of symptoms and that this will need help and some 
extra time to accomplish, possibly on another day.
This does not need to take long but provides 
a powerful signal that someone authoritative 
is listening. It is also important to gain an 
understanding of how the patient manages their 
chronic breathlessness and seeks help. Those who 
actively engage in their care using a problem-solving 
approach and pro-active self-management [42] 
are most likely to maximise their quality of life. 
This has recently been discussed in a framework 
concept called “breathing space” [43]. Specialist 
psychological help may be needed to help 
people achieve this. Effective symptom control 
improves clinical outcomes, for example moving 
an individual from category D in the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) 
classification to category C [1]. No drug therapy 
currently achieves this.
Managing chronic breathlessness
An understanding of the generation of breathless-
ness underlines the need for the clinician to:
●● Listen to the patient’s experience of chronic 
breathlessness (box 2), which will give clues to 
“priors” (e.g. previous experiences) that trigger 
breathlessness and the possible predominant 
vicious cycle, which can be tackled first.
●● Understand how the patient (and carer) view 
the genesis of breathlessness to help overcome 
misconceptions that lead to cognitions and 
emotions that may drive or exacerbate the 
sensation.
●● Help the patient and carer to understand 
the genesis of breathlessness so that when 
psychological or behavioural interventions are 
suggested, rather than a drug treatment, the 
patient and carer can understand the possible 
benefits.
●● Support the patient and carer to self-manage 
breathlessness where they can, which often 
requires difficult changes in their own approach 
and behaviour. Motivational interviewing 
techniques can be very helpful. The importance 
of the clinician’s attention to the symptom in 
addition to the medical condition has been 
highlighted [4, 7, 18].
●● Develop a “ritual for crises” with the patient 
and carer [18, 41]. This will enable patient and 
carer to be ready to tackle an exacerbation of 
breathlessness, which helps shifts the power 
balance towards patient and carer and away 
from seemingly random breathlessness [40]. 
Mularski et al. [41] discussed an approach to 
managing acute-on-chronic breathlessness 
episodes and “rituals for crises” have been a 
mainstay of the CBIS management approach 
since its inception [18]. Involving the carer 
is critical (as discussed later), as a feeling of 
powerlessness in the face of terrifying suffering 
Box 3 Patients with advanced respiratory disease particularly at risk of not receiving appropriate person-centred care
●● Those with rare diseases (e.g. LAM) in areas where multiprofessional respiratory support is organised around common 
diseases; therefore, these patients are ineligible for respiratory nurses whose remit is only for COPD/ILD.
●● Those with respiratory symptoms secondary to a non-respiratory disease, e.g. breathlessness associated with 
neurological or renal disease.
●● Young people with chronic disease and breathlessness, who often have a rare disease.
●● Elderly people with multimorbidities, who may be considered too old to improve or too complicated to manage.
●● Those with sensory disabilities such as blindness and deafness, because of inadequate training of clinical staff or 
inadequate support for clinical staff in caring for people with these needs.
●● Those who have learning disabilities, who need specialist partnerships between those in respiratory medicine/palliative 
care and learning disability care.
●● Socially disadvantaged patients, e.g. with low income, unemployed, on benefits, travellers, the homeless.
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Table 3 Key non-pharmacological interventions used in managing breathlessness, with selected references
Intervention Predominant 




Evidence origin Practical comment
Pulmonary 
rehabilitation
Functioning ++++ Cochrane [47] Patient may lack confidence and need one-to-one 
support or breathlessness service first.
Hand-held fan Breathing +++ [48, 49] Evidence suggests this reduces breathlessness 
recovery time, supports exercise, increases self-
efficacy. No important adverse effects, use in all 
patients, giving advice on how/why used.
Cognitive behavioural 
therapy
Thinking ++ [9, 50] May require specialist psychological support.




Breathing ++ [9] Needs to be personalised, specialist respiratory 
physiotherapy advice required.
Pedometer Functioning ++ [9] Pedometer training, e.g. as used by CBIS, increasing 
activity by 5% weekly from baseline.
Mindfulness-based 
stress reduction
Thinking ++ [9] Requires 8-week course in standard evaluated 
form. Needs formal teaching even in abbreviated 
form.
Relaxation Breathing ++ [9] Various techniques, needs to be personalised.
Walking aids Functioning ++ [51] Should be standard assessment for every 
breathless individual, also possibly affects thinking 
via confidence.
Positioning Breathing + [9] Best position for individual may not fit standard 
ideas.
Acupuncture Breathing? + [9] Needs specialist training.
Box 4 Role of specialist breathlessness services
●● There is increasing evidence for the effectiveness of a complex mostly non-pharmacological intervention to help 
breathlessness of all severities, delivered by a specialist breathlessness or advanced respiratory disease specialist clinic.
●● A complex intervention is one that combines several components that may be used together or separately, by an 
individual or different individuals.
●● The most effective treatments for breathlessness are delivered by a multiprofessional team. This a process, rather than 
an event, which may need to be revisited from time to time after the initial treatment period is completed.
●● There is now good evidence that specialist breathlessness services and/or early integration of palliative care can improve 
care quality [4, 56], and emerging evidence that advanced respiratory disease clinics can improve quality of care and 
patient satisfaction while maintaining or reducing healthcare costs [54, 58].
Box 5 Practical tips for busy clinics: referring to palliative care
If you do not practise in an advanced lung disease clinic [54, 59, 60], assessing and managing breathlessness will need to be a 
staged, shared procedure with someone taking a coordinating role. Clearly this cannot be a rushed discussion brought up as an 
afterthought with severe time pressures. It does not have to be completed in one session. If your patient is very symptomatic 
and basic breathlessness interventions have not helped, or if the patient has had several recent hospital admissions unrelated 
to exacerbation or severe infection, is very cachectic or rarely leaves the house, or if you feel that another episode of ventilation 
in an intensive therapy unit will not be of long-term benefit, they may benefit from specialist palliative care [4, 44, 45]. Family 
or carer distress is another possible reason for referral.
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in a loved one is extremely stressful and more 
likely to lead to an out-of-hours admission. As 
the work of Linde et al. [40] has demonstrated, 
there is usually a precipitator of apparently 
inexplicable episodes of breathlessness.
●● Refer to specialist palliative care. This is 
advised when 1) breathlessness is having a very 
significant impact on the quality of life of the 
patient or family, 2) there have been multiple 
hospital admissions or consultations irrelevant 
to disease management [4, 44–46], 3) there 
are extra barriers to giving the patient and 
family excellent care (box 3 and table 2), and 4) 
where there is insufficient expertise within the 




The most common interventions (and those 
with greatest evidence base individually) are 
shown in table 3. Three Cochrane reviews of non-
pharmacological interventions (to map against the 
three BTF cycles) are under way [46, 52, 53] and 
will report soon.
It is likely that active listening and promotion of 
the therapeutic alliance [18] involved in effective 
assessment is an intervention in itself. Specific 
breathlessness interventions are not all provided 
at once [37], and not everyone needs every 
intervention. Even so, many respiratory physicians 
working in outpatient clinics, or clinicians with a 
priority such as managing inhaler technique, will 
be concerned about how they will find time to 
integrate them into practice. Remember, when very 
time-constrained, specific interventions are initially 
less important to a patient than the attention, 
support and affirmation of their difficulties from 
an interested, knowledgeable, professional, kindly 
clinician [4, 16, 17]. Specific interventions should 
be part of the care, not a list of actions or techniques 
given as a substitute for excellent personalised 
assessment and support.
Best practice is a fully integrated respiratory 
service with a multiprofessional team who have an 
interest in advanced respiratory disease and access 
to specialist palliative care when needed [2–4, 
54, 55], or access to a specialist breathlessness 
service [56, 57] or to a palliative care service working 
closely with respiratory medicine [16, 17, 44, 45].
Where these do not exist, the patient may still 
be given good care for breathlessness and other 
symptoms by ensuring the resources within 
respiratory medicine, palliative care and primary 
care work closely together.
A suggested algorithm for care where no 
specialist advanced respiratory disease clinic or 
breathlessness service operates is shown in figure 5. 
More information on each step has been given in 
the text and boxes 2, 4 and 5, and figure 6 [61] 
highlights the balance between drug and non-drug 
interventions.
Drug therapy for chronic 
breathlessness
There is a limited range of drugs used in the 
management of chronic breathlessness. The 
principal one in routine clinical practice is morphine 
(box 6). Mirtazapine is beginning to be more widely 
used on the basis of its neurochemistry, therapeutic 
profile, and some clinical experience. Data collection 
in a phase 3 trial is starting soon (BETTER-B; 
ISRCTN registry, identifier ISRCTN32236160). A 
recent phase 3 placebo-controlled randomised 
controlled trial of sertraline failed to demonstrate 
benefit over placebo [65]. Benzodiazepines are 
used appropriately for dying patients [66] but 
their dependency potential and lack of evidence 
for effectiveness makes them unsuitable for long-
term use for symptom control. Furosemide and 
cannabinoids show promise [67] but will not be 
further discussed as they are not used outside trials. 
Drug therapy aims to improve quality of life by 
reducing breathlessness, and patient assessment is 
key. It is crucial that patients are given drug therapy 
for chronic breathlessness when needed, but not as 
a first option, except when patients are extremely 
breathless and have no prospect of improvement 
(figure 6) [61].
The recent scandals around inappropriate use of 
opioids in chronic non-malignant pain (see box 7) 
are likely to increase patients’ and some physicians’ 
fear of opioids, so it is important that the reason for 
prescribing is clear.
Prescribing drugs should not be a lazy reflex 
because non-drug interventions (appropriate 
for every patient) seem too complex or time-
consuming. Drug interventions are not required 
for every breathless patient. Different non-drug 
interventions will be needed at different stages of 
the disease, along a continuum from principally 
rehabilitative to principally supportive. Slowing 
the rate of deterioration and optimising general 
health in a progressive disease is improvement. 
Morphine is the drug with the best evidence base 
[68] and is prescribed orally, with the largest 
effect sizes seen in steady state. After review 
of effectiveness and safety data, it now has an 
extended licensed indication in Australia (from the 
Therapeutic Goods Administration) that includes 
chronic breathlessness, to use at 10–30 mg·day−1 
of sustained-release oral morphine (Kapanol) after 
individual assessment (box 6). Start on the lowest 
possible dose [63], increasing where necessary to 
20 mg daily modified-release form and titrate up, 
if needed, to a maximum of 30 mg daily, treating 
adverse effects actively. Most patients in clinical 
trials have required no more than 30 mg·day−1, but 
it should be noted that two-thirds of patients had 
stopped morphine at 3 months because of adverse 
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effects or lack of response [64], so it is clear that 
it does not help everyone. There are some non-
placebo-controlled reports of benefit from lower 
doses [18, 59, 61].
Oral morphine (box 6) is indicated: 1) in 
the palliative care of patients with distressing 
breathlessness due to severe COPD, heart failure, 
cancer or other causes, 2) after treatments for the 
underlying cause(s) of the breathlessness have been 
optimised and non-pharmacological treatments are 
not effective, and 3) when initiated by a specialist 
knowledgeable in its use.
It is important to note that a recent study 
indicated that in patients with pulmonary arterial 
hypertension [58], morphine was unhelpful, even 
making the sensation worse in some individuals. We 
cannot assume that morphine will be beneficial in all 
diseases or in all individuals, so careful monitoring is 
needed. Most of the research in morphine has been 
conducted in people with COPD and there is still 
much to learn. Fortunately, there are a number of 
trials underway in patients with cancer, ILD and COPD 
(e.g. ClinicalTrials.gov NCT02429050, for COPD).
Ongoing review is important, and it may be 
possible to stop morphine when the patient has 
improved and has, for example, been able to 
engage with exercise or cognitive approaches to 
their breathlessness. Once prescribed, patients 
therefore need to be monitored to see if the dose 
needs increasing, decreasing or stopping, and to 
optimise management of adverse effects. Most 
people with breathlessness who are prescribed 
morphine will have progressive disease or end-stage 
disease, as in other patients, non-pharmacological 
approaches will be the safest and most appropriate 
choice. Respiratory depression has been a concern 
historically, but in selected patients with appropriate, 
individualised dose schedules and monitoring, 
these fears appear to be unfounded [63]. There is 
no indication to use other opioids outside clinical 
trials or specialist centres. Mirtazapine may be a 
better first alternative if depression, severe anxiety 
or sleeplessness predominate, although phase 3 
data are lacking [69].
Fatigue
Fatigue is the most common symptom of every 
illness and equally commonly overlooked. It is 
highly prevalent in advanced respiratory disease 
[70, 71]. Fatigue is not simple tiredness but 
“incorporates total body feelings, ranging from 
tiredness to exhaustion, creating an overall body 
condition which is unrelenting and alters the 
person’s ability to function” [71]. Characteristically, 
it is not improved by sleep or rest. In spite of this, 
fatigue is often seen by clinicians as normal, or 
to be expected, and untreatable, only remediable 
by recovery from illness (impossible in advanced 
respiratory disease). Fortunately, many of the 
treatments for breathlessness help fatigue as well, 
particularly exercise, cognitive behavioural therapy 
and pacing and prioritising [72]. It is also important 
to assess patients’ sleep patterns and quality, as 
poor sleep contributes to fatigue.
Many patients who mention fatigue feel belittled 
by clinicians, relatives or the general public, who 
confuse fatigue with tiredness. It is particularly 
difficult in these circumstances to explain that 
appropriate exercise is likely to help (initially 
supported by a physiotherapist, then integrated into 
day-to-day living). It is counter-intuitive and may 
be interpreted as implying that patients have not 
tried hard enough to help themselves. It is useful 
that pulmonary rehabilitation, backed by a wealth 
of evidence, can improve breathlessness [47]. As 
an exercise-based intervention it is the ideal place 
to start for those fit enough. Participants also make 
social connections, another benefit to health. If 
the patient is too breathless for this (rarer now as 
there is often specialist provision for severe disease), 
Initiate and optimise opioid therapies:
  Short- and long-acting agents
Initiate and optimise non-pharmacological therapies:
  Exercise, pursed-lip breathing, walking aids, chest wall vibration, NMES
Initiate and optimise pharmacological therapies:








Figure 6 The breathlessness ladder. Comprehensive approach to the management of dyspnoea in patients with advanced 
COPD. NMES: neuromuscular electrical stimulation; SABD: short-acting bronchodilators; LAAC: long-acting anticholin-
ergics; ICS: inhaled corticosteroids; LABA: long-acting β2-agonists; PDE4: phosphodiesterase-4. Reproduced and modified 
from [61] with permission.
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then a hospice rehabilitation service may help to 
co-design a personalised exercise programme with 
the patient. It is important to remember that rest 
rather than exercise during periods of deterioration 
or infection is needed as the inflammatory response 
is likely to be active at these times.
Cough
This can be a very distressing symptom, and a 
precipitator and exacerbator of breathlessness, 
anxiety and poor sleep in both the sufferer and those 
closest to them [73]. The social embarrassment 
and discomfort can lead to social isolation; it may 
even be associated with impatience and irritation in 
those around the patient, which adds to the distress 
of the symptom.
A non-pharmacological intervention based on 
speech and language therapy has been used in 
chronic (idiopathic) cough [74] with some success. 
Yorke et al. [21] have also used a psychoeducational 
approach in cough, fatigue and breathlessness 
in cancer patients, which showed promise in a 
large pilot study and is currently being tested in 
a randomised controlled trial. While both of these 
approaches need training, some elements will be 
available within standard respiratory services (e.g. 
physiotherapy) or within the wider service (e.g. 
speech and language service).
Drug therapy is imperfect: gabapentin, a central 
modulator of cough generation, is used but there 
is no guidance for its use in advanced respiratory 
disease [75]. Taking 10 mg of oral modified-
release morphine daily has been shown to cause 
a statistically significant 40% reduction in cough 
scores compared with placebo [76]. Considerations 
apply with regard to individualising dose, active 
monitoring of dosing regimen and adverse effects, 
similar to those for breathlessness management. 
Long-term use of opioids is not recommended. 
More promising agents are being evaluated, such 
as P2X3 and aprepitant (in cancer patients), but 
have not been tested in people with advanced 
respiratory disease.
Psychological aspects of care
Anxiety and breathlessness are inextricably 
linked, as humans are hard-wired to breathe, and 
avoidance of suffocation is an evolutionary response 
partly imprinted by feelings as an adaptive response 
[77]. For many patients (and carers), being listened 
Box 6 Morphine: drug portrait
●● Principal alkaloid in opium, although most morphine is now synthetic (therefore opioid, not opiate).
●● Powerful mu agonist, with effects on areas rich in mu receptors: brain stem, posterior amygdala, hypothalamus, 
thalamus, nucleus caudatus, putamen, certain cortical areas, and the lungs.
●● Mu receptors also common in spinal cord/gastrointestinal tract.
●● Some analgesic activity from metabolites of morphine (M3G, M6G).
●● Adverse effects mediated through other receptors, e.g. kappa and delta.
●● Strong analgesic: not recommended for long-term use in non-malignant pain after recent misuse and high levels of 
opioid addiction primarily related to oxycodone (see box 7).
●● Available in immediate-release and modified-release forms.
●● Undergoes significant first-pass metabolism, hence variation in level after same dose in different people.
●● Most common adverse effects need active management (e.g. treatment of nausea and vomiting or constipation) or 
reduction in dose and then slow titration upwards again (e.g. sedation) [62–64].
●● Adverse effects of opioids may be limiting factor in patients accepting treatment, hence initiate low dose and increase 
slowly (wait at least 7 days before dose titration).
●● Modified-release form should not be used in those with significant renal/hepatic impairment (e.g. estimated glomerular 
filtration rate <25 mL·min−1) due to accumulation risk from active metabolites; care should also be taken in elderly/frail/
cachectic patients for the same reason.
●● The principle (as in other prescribing) is to use minimum effective dose for shortest time.
Licensed preparation (Therapeutic Goods Administration, Australia)
●● Sustained-release morphine (10 mg/24 h; 20 mg/24 h capsules) as Kapanol# now has an extension to its licensed 
indication to include chronic breathlessness.
●● Should only be used in the palliative care of patients with “distressing breathlessness due to severe COPD, cardiac 
failure, malignancy or other cause, after treatments for the underlying cause(s) of the breathlessness have been 
optimised and non-pharmacological treatments are not effective”.
●● Dose: start at 10 mg·day−1, and limit to maximum of 30 mg·day−1.
●● Must be initiated by a specialist knowledgeable in its use.
#: although many countries do not have access to Kapanol, most have access to modified/sustained-release preparations that allow similar 
steady-state blood levels; total initial daily starting dose can be 10 mg in 24 h on Kapanol.
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to is an important first step [4, 7, 10, 16, 17], and 
education about breathlessness is the second step 
in reducing anxiety. Use of the BTF model can be 
helpful in understanding and explaining how anxiety 
feeds in to breathlessness and how it is fed by the 
sensation, as well as ways to break these cycles. 
Access to specialist psychological support, where 
the therapist understands breathlessness, can be 
invaluable where this is needed. A recent systematic 
review demonstrated that drug treatment can be 
very effective for “trait” (i.e. part of the individual’s 
make-up) anxiety and may have the additional 
benefit of helping to contain breathlessness [78].
Depression
Depression is associated with poorer clinical 
outcomes in advanced respiratory disease [79]. 
Again, it needs to be actively sought, and many 
clinics now use the Hospital Anxiety and Depression 
Scale (HADS) as a screening tool. If it is detected, 
depression must be actively treated.
Nutrition
The role and importance of the gut and lung 
microbiomes for psychological and physical 
health, including containing the inflammatory 
response, are becoming increasingly understood 
[80]. While there are no clear guidelines for the 
health of the lung microbiome, it is known that, 
for optimum gut health, individuals should eat a 
wide variety of foods, with a high proportion of 
fibre, wholegrains, vegetables and fruit, and with 
a low proportion of processed foods and those 
high in refined sugars, particularly fructose [81]. A 
healthy diet will also prevent the onset of metabolic 
syndrome, facilitate activity and reduce the impact 
of cumulative morbidity of both disease and drugs 
such as steroids.
Adequate sleep
Good quality and adequate amounts of sleep are 
needed for optimum health, both psychological 
and physical, including symptom control (e.g. 
fatigue) and containing inflammatory risk [82]. 
There is an increased incidence of sleep problems 
in people with chronic illness and some may be 
particularly important in advanced respiratory 
disease (e.g. nocturnal hypoxia). It is important that 
a detailed sleep history is taken, as some problems 
may need specialist help. All clinic patients (and 
carers) need to be aware of the importance of good 
sleep habits.
Carers
Living with someone with advanced respiratory 
disease is emotionally stressful, physically 
demanding [10, 11, 16] and imposes serious 
restrictions on the individual aspirations of the carer. 
Health services do not generally fund carer support 
as an intrinsic part of service delivery. Education 
and training about optimising symptom control, 
improving self-management, initiating a ritual 
for crises that involves the carer, and facilitating 
discussion of difficult issues (like the strain the carer 
is under) may all help to ease these. Farquhar 
et al. [83] are developing some tools (Support Needs 
Assessment for Patients (SNAP)) and educational 
programmes (Living With Breathlessness (LWB)) 
that may help in this area in the future. It is always 
important to listen to carers’ concerns, acknowledge 
their efforts and encourage them to look after their 
own health and take some time for themselves 
[4, 16, 17]. This may be an area where specialist 
palliative care can help, as carer support is intrinsic 
to the specialty.
Optimising general health
An additional advantage of the non-pharmacological 
approach to breathlessness and fatigue (including 
better sleep and nutrition) is that it builds an 
individual’s general health. People with chronic 
illness live stressful lives (and so do their carers). 
The stress response, if prolonged, will contribute 
to “inflammaging” [84, 85] and symptom 
exacerbation (well-reviewed elsewhere [60]). This 
is another rationale to help patients see the value 
Box 7 The opioid epidemic in the USA, and its possible global impact
In 2018, there were 6000 deaths from opioid overdose in the USA. These deaths were mainly in young people who had first become 
addicted to opioids from legally available drugs, some then switching to other more potent opioids from illegal sources. Many of 
those affected came from stable, middle-class backgrounds where a family member had a short, limited course of opioids, e.g. 
after a surgical intervention. The epidemic of addiction has had profound societal effects and is beginning to affect the status of 
opioids for medical use, e.g. shorter post-operative prescription of drugs, withdrawal of use of opioids for non-malignant pain. 
It may yet have further effects as legal action is taken against drug companies for use of misleading information in “selling” of 
opioids. It’s important to be aware of the dependency potential of opioids and to ensure that family members know the dangers 
of using the patient’s pain and breathlessness medication. On 28 April 2019, the Department of Health (UK) announced it was 
putting health warnings on drug packages containing opioids, both prescribed and those sold “over the counter”.
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of committing to necessary behaviour change. It 
is also helpful to explain that mind, body and brain 
are interconnected [86] and that improvement in 
one helps to drive improvement in another. It also 
makes it easier for the carer to understand the need 
to look after their own health actively. The “five ways 
to well-being” outlined in box 1 provide a framework 
to help individuals optimise their general health.
Advanced care planning
Although this might seem like an odd topic for an 
article on improving quality of life, it is clear that, 
with good reason, 1) many patients with advanced 
respiratory disease and their carers worry about their 
future and how they will be if/when the disease gets 
worse, and 2) patients expect doctors to initiate 
relevant discussions about end-of-life care [87]. 
The respiratory clinician who knows the patient and 
their illness is well placed to help patients make 
informed choices. There are also some patients who 
do not realise that advanced COPD, for example, is 
a life-threatening illness. All the available evidence 
suggests that patients with advanced respiratory 
disease would like to discuss possible options for 
end-of-life care and the use of invasive potentially 
life-sustaining interventions if they are gravely ill 
[87]. Support from specialist palliative care will help 
improve the choices available to the patient and 
family for care and support. The respiratory clinician 
needs to initiate these discussions. There are many 
papers in the literature that discuss possible timings 
of these discussions [24, 44, 87] and it may be 
decided with primary care or specialist palliative 
care that they are best placed to talk about options.
Conclusions
Person-centred care of those suffering with 
advanced respiratory disease is the most effective 
way of improving quality of life and clinical 
outcomes, and of reducing wasteful ineffective care 
that further exhausts and demoralises patients and 
families. It is not a one-off event but a process, 
and involves the whole respiratory multidisciplinary 
team working closely with primary and specialist 
palliative care.
Advanced respiratory disease is associated 
with some of the most difficult symptom-
control and quality-of-life problems in medicine, 
sometimes over many years. The respiratory 
clinician, with their specialist knowledge and 
personal relationship with the patient, has an 
obligation to ensure that advanced respiratory 
disease is managed effectively. Every clinical 
encounter is an opportunity to improve quality 
of life for that patient and family. Use of specialist 
skills of other teams, like palliative and primary 
care, as soon as possible [4], will ensure that 
person-centred care is seamless, reducing 
suffering and optimising health throughout the 
patient’s life.
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